Treatment for Brain Metastases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Brain Metastases
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether fractionated stereotactic radiosurgery (FSRS) is a feasible treatment option for people with no prior whole brain radiation.

Eligible Conditions
  • Brain Metastases

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 3 years

Year 5
Functional Assessment of Cancer Therapy - Brain (FACT-Br)
Up to 3 years
Local control of disease
Maximum tolerated dose (MTD)
Adrenal gland hypofunction

Trial Safety

Trial Design

0 Treatment Group

25 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Steven BurtonLead Sponsor
3 Previous Clinical Trials
224 Total Patients Enrolled
Steve Burton, MDPrincipal InvestigatorUniversity of Pittsburgh
1 Previous Clinical Trials
174 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a male or female patient ≥ 18 years of age.
You have 3 or more distinct lesions within the brain.
You are on steroids or anti-epileptics.
You have no prior radiotherapy to the brain.
You have a target lesion(s) that can be accurately measured in at least one dimension according to RECIST.
The additional lesions will each be treated with single fraction stereotactic radiosurgery.
At least 1 lesion must be a minimum of 3cm in greatest dimension, no larger than 5cm which will be treatable by fractionated stereotactic radiosurgery.